期刊
JOURNAL OF SEXUAL MEDICINE
卷 12, 期 8, 页码 1660-1686出版社
ELSEVIER SCI LTD
DOI: 10.1111/jsm.12952
关键词
Testosterone Deficiency; Hypogonadism; Etiology of Hypogonadism; Assessment of Hypogonadism; Treatment of Hypogonadism
资金
- Allergan
- Evidera
- Ixchelsis
- Palatin
- Menarini
- NIH
- Urology Care Foundation
- AUA
- AMS
- Coloplast
- Bayer-Schering
- Besins
- Lilly
- Pfizer Inc.
- Auxilium
- Endo Pharmaceuticals
- Theralogix
- Ibsa
- Bayer
- Intercept
- Ely Lilly
- Prostrakan
- Antares
- Warner Chilcott
- Repros
- Capital Region Medical Foundation
- Janssen Cilag
- Johnson and Johnson
- Endo
- Eli Lilly
IntroductionIn 2014, the International Society for Sexual Medicine (ISSM) convened a panel of experts to develop an evidence-based process of care for the diagnosis and management of testosterone deficiency (TD) in adult men. The panel considered the definition, epidemiology, etiology, physiologic effects, diagnosis, assessment and treatment of TD. It also considered the treatment of TD in special populations and commented on contemporary controversies about testosterone replacement therapy, cardiovascular risk and prostate cancer. AimThe aim was to develop clearly worded, practical, evidenced-based recommendations for the diagnosis and treatment of diagnosis and management of TD for clinicians without expertise in endocrinology, such as physicians in family medicine and general urology practice. MethodA comprehensive literature review was performed, followed by a structured, 3-day panel meeting and 6-month panel consultation process using electronic communication. The final guideline was compiled from reports by individual panel members on areas reflecting their special expertise, and then agreed by all through an iterative process. ResultsThis article contains the report of the ISSM TD Process of Care Committee. It offers a definition of TD and recommendations for assessment and treatment in different populations. Finally, best practice treatment recommendations are presented to guide clinicians, both familiar and unfamiliar with TD. ConclusionDevelopment of a process of care is an evolutionary process that continually reviews data and incorporates the best new research. We expect that ongoing research will lead to new insights into the pathophysiology of TD, as well as new, efficacious and safe treatments. We recommend that this process of care be reevaluated and updated by the ISSM in 4 years. Dean JD, McMahon CG, Guay AT, Morgentaler A, Althof SE, Becher EF, Bivalacqua TJ, Burnett AL, Buvat J, El Meliegy A, Hellstrom WJG, Jannini EA, Maggi M, McCullough A, Torres LO, and Zitzmann M. The International Society for Sexual Medicine's process of care for the assessment and management of testosterone deficiency in adult men. J Sex Med 2015;12:1660-1686.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据